Chong Kun Dang Pharmaceutical

This study tests a new drug called CKD-703 in people with advanced solid tumors or non-small cell lung cancer that has a specific protein (c-Met). The drug is designed to attach to cancer cells and release chemotherapy directly inside them, aiming to kill the cancer while reducin…

This early-stage study tests a new drug called CKD-512, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 60 participa…

This early-stage trial tests a new drug called CKD-706, which is a biosimilar (a close copy) of the approved eczema treatment Dupixent. The study involves 519 healthy adults who will receive a single injection of either CKD-706, the US version of Dupixent, or the European version…

This Phase 1 trial tests a new biosimilar called CKD-704, which is designed to be a more affordable copy of the psoriasis drug Skyrizi (risankizumab). The study involves 213 healthy adults who will receive a single dose of either CKD-704, the EU-approved Skyrizi, or the US-licens…

This phase 3 trial tests whether a combination pill containing sacubitril and valsartan (CKD-202A) works better than valsartan alone for essential hypertension. About 324 adults with high blood pressure will take either the combo or the standard drug for 10 weeks. The main goal i…